DEXCOM, INC.— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2025 (Q4)
Revenue
$1.19B
↑+15.0% +$156Mvs FY2025 (Q4)
Gross Profit
$750M
↑+27.4% +$161Mvs FY2025 (Q4)
Operating Income
$255M
↑+90.9% +$122Mvs FY2025 (Q4)
Net Income
$200M
↑+89.3% +$94Mvs FY2025 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2025 (Q4) |
|---|---|---|
| Revenue | $1.19B | $1.04B |
| COGS | $442M | $447M |
| Gross Profit | $750M | $589M |
| R&D | $145M | $145M |
| SG&A | $350M | $310M |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $255M | $134M |
| Interest Exp. | $2M | $4M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $253M | $130M |
| Tax | $54M | $25M |
| Net Income | $200M | $105M |
QuarterCharts · SEC EDGAR data · DXCM · Comparing FY2026 (Q4) vs FY2025 (Q4)